Publications
57 results found
Ritchie C, 2014, Expanding the mind - growing the brain . . ., INTERNATIONAL PSYCHOGERIATRICS, Vol: 26, Pages: 889-889, ISSN: 1041-6102
Ritchie CW, Newman TH, Leurent B, et al., 2014, The association between C-reactive protein and delirium in 710 acute elderly hospital admissions, INTERNATIONAL PSYCHOGERIATRICS, Vol: 26, Pages: 717-724, ISSN: 1041-6102
- Author Web Link
- Cite
- Citations: 22
Ritchie CW, Bajwa J, Coleman G, et al., 2014, SOUVENAID (R): A NEW APPROACH TO MANAGEMENT OF EARLY ALZHEIMER'S DISEASE, JOURNAL OF NUTRITION HEALTH & AGING, Vol: 18, Pages: 291-299, ISSN: 1279-7707
- Author Web Link
- Cite
- Citations: 15
McGhee DJM, Ritchie CW, Thompson PA, et al., 2014, A Systematic Review of Biomarkers for Disease Progression in Alzheimer's Disease, PLOS ONE, Vol: 9, ISSN: 1932-6203
- Author Web Link
- Cite
- Citations: 37
Ritchie CW, Wells K, Ritchie K, 2013, The PREVENT research programme - A novel research programme to identify and manage midlife risk for dementia: the conceptual framework, INTERNATIONAL REVIEW OF PSYCHIATRY, Vol: 25, Pages: 748-754, ISSN: 0954-0261
- Author Web Link
- Cite
- Citations: 7
Ames D, Ritchie CW, 2013, Prospective cohort studies in dementia, INTERNATIONAL REVIEW OF PSYCHIATRY, Vol: 25, Pages: 647-649, ISSN: 0954-0261
Leroi I, Woolham J, Gathercole R, et al., 2013, Does telecare prolong community living in dementia? A study protocol for a pragmatic, randomised controlled trial, TRIALS, Vol: 14, ISSN: 1745-6215
- Author Web Link
- Cite
- Citations: 31
Avent C, Curry L, Gregory S, et al., 2013, Establishing the motivations of patients with dementia and cognitive impairment and their carers in joining a dementia research register (DemReg), INTERNATIONAL PSYCHOGERIATRICS, Vol: 25, Pages: 963-971, ISSN: 1041-6102
- Author Web Link
- Cite
- Citations: 11
NoelStorr AH, Flicker L, Ritchie CW, et al., 2013, Systematic review of the body of evidence for the use of biomarkers in the diagnosis of dementia, Alzheimer's & Dementia, Vol: 9, ISSN: 1552-5260
Ritchie CW, Zhinchin G, 2013, Low dose, high dose, or no dose: better prescribing of cholinesterase inhibitors for Alzheimer's disease, INTERNATIONAL PSYCHOGERIATRICS, Vol: 25, Pages: 511-515, ISSN: 1041-6102
- Author Web Link
- Cite
- Citations: 5
Flicker L, McShane R, Noel-Storr A, et al., 2012, Harmonisation of reporting for studies of diagnostic accuracy in dementia, AUSTRALASIAN JOURNAL ON AGEING, Vol: 31, Pages: 19-19, ISSN: 1440-6381
Ruffmann C, Bravi I, Calboli FCF, et al., 2012, Dementia in Lewy body disorders: clinicopathological correlations in a large sample from the Parkinson's UK Tissue Bank, 16th Congress of the European-Federation-of-Neurological-Societies (EFNS), Publisher: WILEY-BLACKWELL, Pages: 72-72, ISSN: 1351-5101
Flicker L, Noel-Storr A, Ritchie CW, et al., 2012, A systematic review of the quality and reporting standards of longitudinal biomarker studies in dementia, AUSTRALASIAN JOURNAL ON AGEING, Vol: 31, Pages: 18-18, ISSN: 1440-6381
Howard R, McShane R, Lindesay J, et al., 2012, Donepezil and memantine for moderate-to-severe Alzheimer's disease, New England Journal of Medicine, Vol: 10, Pages: 957-959
BACKGROUND: Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer's disease. It is not known whether treatment benefits continue after the progression to moderate-to-severe disease.METHODS: We assigned 295 community-dwelling patients who had been treated with donepezil for at least 3 months and who had moderate or severe Alzheimer's disease (a score of 5 to 13 on the Standardized Mini-Mental State Examination [SMMSE, on which scores range from 0 to 30, with higher scores indicating better cognitive function]) to continue donepezil, discontinue donepezil, discontinue donepezil and start memantine, or continue donepezil and start memantine. Patients received the study treatment for 52 weeks. The coprimary outcomes were scores on the SMMSE and on the Bristol Activities of Daily Living Scale (BADLS, on which scores range from 0 to 60, with higher scores indicating greater impairment). The minimum clinically important differences were 1.4 points on the SMMSE and 3.5 points on the BADLS.RESULTS: Patients assigned to continue donepezil, as compared with those assigned to discontinue donepezil, had a score on the SMMSE that was higher by an average of 1.9 points (95% confidence interval [CI], 1.3 to 2.5) and a score on the BADLS that was lower (indicating less impairment) by 3.0 points (95% CI, 1.8 to 4.3) (P<0.001 for both comparisons). Patients assigned to receive memantine, as compared with those assigned to receive memantine placebo, had a score on the SMMSE that was an average of 1.2 points higher (95% CI, 0.6 to 1.8; P<0.001) and a score on the BADLS that was 1.5 points lower (95% CI, 0.3 to 2.8; P=0.02). The efficacy of donepezil and of memantine did not differ significantly in the presence or absence of the other. There were no significant benefits of the combination of donepezil and memantine over donepezil alone.CONCLUSIONS: In patients with moderate or severe Alzheimer's disease, continued treat
Shearer J, Green C, Ritchie CW, et al., 2012, Health State Values for Use in the Economic Evaluation of Treatments for Alzheimer's Disease, DRUGS & AGING, Vol: 29, Pages: 31-43, ISSN: 1170-229X
- Author Web Link
- Cite
- Citations: 36
Ritchie K, Ritchie CW, 2012, Mild cognitive impairment (MCI) twenty years on, INTERNATIONAL PSYCHOGERIATRICS, Vol: 24, Pages: 1-5, ISSN: 1041-6102
- Author Web Link
- Cite
- Citations: 13
Ritchie CW, Ritchie K, 2012, The PREVENT study: a prospective cohort study to identify mid-life biomarkers of late-onset Alzheimer's disease, BMJ OPEN, Vol: 2, ISSN: 2044-6055
- Author Web Link
- Cite
- Citations: 59
Ritchie C, Smajlagic N, McShane R, et al., 2011, Biomarkers: The weight of the evidence, INTERNATIONAL PSYCHOGERIATRICS, Vol: 23, Pages: S306-S306, ISSN: 1041-6102
Lautenschlager N, Burke W, O'Brien J, et al., 2011, Meet the Editors of International Psychogeriatrics and the IPA Bulletin or everything you always wanted to know about Editors, but were afraid to ask, INTERNATIONAL PSYCHOGERIATRICS, Vol: 23, Pages: S50-S50, ISSN: 1041-6102
Ritchie CW, Ames D, Burke JR, et al., 2011, An international perspective on advanced neuroimaging: cometh the hour or ivory tower?, INTERNATIONAL PSYCHOGERIATRICS, Vol: 23, Pages: S58-S64, ISSN: 1041-6102
- Author Web Link
- Cite
- Citations: 3
Howard R, Phillips P, Johnson T, et al., 2011, Determining the minimum clinically important differences for outcomes in the DOMINO trial, INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, Vol: 26, Pages: 812-817, ISSN: 0885-6230
- Author Web Link
- Cite
- Citations: 108
Green C, Shearer J, Ritchie CW, et al., 2011, Model-Based Economic Evaluation in Alzheimer's Disease: A Review of the Methods Available to Model Alzheimer's Disease Progression, VALUE IN HEALTH, Vol: 14, Pages: 621-630, ISSN: 1098-3015
- Author Web Link
- Cite
- Citations: 47
Wilson D, Peters R, Ritchie K, et al., 2011, Latest Advances on Interventions that May Prevent, Delay or Ameliorate Dementia., Ther Adv Chronic Dis, Vol: 2, Pages: 161-173, ISSN: 2040-6223
OBJECTIVES: IN THIS PAPER WE AIM TO: (1) identify and review midlife risk factors that may contribute to the development of dementia and that may be amenable to intervention; (2) review advances made in our understanding of the most common cause of dementia, Alzheimer's disease (AD), where current pharmacological studies have aimed to modify the disease course; and (3) explore other interventions that may slow cognitive decline in those with AD. METHODS: A review of the literature was conducted to look for interventions that may modify the risk of incident dementia or that may modify symptom progression in those with diagnosed dementia. RESULTS: (1) Midlife risks identified as amenable to intervention include blood pressure, diabetes, elevated cholesterol, poor psychosocial and lifestyle factors. (2) The leading drugs in development can be grouped by their principal target: anti-amyloid, anti-tau and mitochondrial stability. However to date, there have been no successes in late stage Phase III trials of putative disease-modifying drugs for AD. (3) Once the diagnosis of dementia has been made there is little that can slow the rate of decline. Possible exceptions include the use of exercise and antihypertensive medication with some nootropic medication showing promise in small trials. CONCLUSION: (1) It is clear that there are several risk factors in midlife that may lead to a greater likelihood of developing dementia. However, there is no simple intervention to modify these risks. It seems sensible to conclude from the data that avoiding high blood pressure, controlling cholesterol and diabetes as well as maintaining a healthy diet and lifestyle may lower the risk of developing dementia. (2) The need for better outcome measures in clinical trials is evident and may, in part, explain the numerous failures in late-stage clinical trials of disease-modifying drugs. Improved diagnostic test batteries to reduce population heterogeneity in early intervention studies will be
Akbaraly TN, Ancelin M-L, Jaussent I, et al., 2011, Metabolic Syndrome and Onset of Depressive Symptoms in the Elderly Findings from the Three-City Study, DIABETES CARE, Vol: 34, Pages: 904-909, ISSN: 0149-5992
- Author Web Link
- Cite
- Citations: 41
Ritchie CW, King MB, Nolan F, et al., 2011, The association between personality disorder and an act of deliberate self harm in the older person, INTERNATIONAL PSYCHOGERIATRICS, Vol: 23, Pages: 299-307, ISSN: 1041-6102
- Author Web Link
- Cite
- Citations: 3
Iliffe S, Curry L, Kharicha K, et al., 2011, Developing a dementia research registry: a descriptive case study from North Thames DeNDRoN and the EVIDEM programme, BMC Medical Research Methodology, Vol: 11, Pages: 1-10, ISSN: 1471-2288
AimTo describe the development of a dementia research registry, outlining the conceptual, practical and ethical challenges, and to report initial experiences of recruiting people with dementia to it from primary and secondary care.BackgroundWomen, the oldest old and ethnic minorities have been under-represented in clinical trials in dementia. Such under-representation biases estimates of absolute effect, absolute harm and cost-effectiveness. Research on dementia should include patient populations that more exactly reflect the population at risk. One of the impediments to this is the lack of a suitable tool for identification of patients suitable for studies.Construction & contentsA technology development methodology was used to develop a registry of people with dementia and their carers. This involved phases of modelling and prototype creation, 'bench testing' the prototype with experts and then 'field testing' the refined prototype in exemplar sites. The evaluation of the field testing described here is based on a case study methodology.UtilityThis case study suggests that construction and population of a dementia research registry is feasible, but initial development is complex because of the ethical and organisational difficulties. Recruitment from primary care is particularly costly in terms of staff time and only identifies a very small number of people with dementia who were not already known to specialist services. Recruiting people with dementia through secondary care is a resource intensive process that takes up to six months to complete. Identifying the components of a minimum dataset was easy but its usefulness for pre-screening potential research populations has yet to be established. Acceptance rates are very high in the first clinic to recruit to the registry, but this may reflect the efforts of registry 'champions'.Discussion and ConclusionsEasier recruitment may perpetuate potential selection biases and we are not yet able to assess the represent
Mason SE, McShane R, Ritchie CW, 2010, Diagnostic tests for Alzheimer's disease: rationale, methodology, and challenges., Int J Alzheimers Dis, Vol: 2010
There has been a large increase in the amount of research seeking to define or diagnose Alzheimer's disease before patients develop dementia. If successful, this would principally have clinical benefits both in terms of treatment as well as risk modification. Moreover, a better method for diagnosing predementia disease would assist research which seeks to develop such treatments and risk modification strategies. The evidence-based definition of a diagnostic test's accuracy is fundamental to achieve the above goals and to address this, the Cochrane Collaboration has established a Diagnostic Test Accuracy group dedicated to examining the utility and accuracy of proposed tests in dementia and cognitive impairment. We present here the assumptions and observations underpinning the chosen methodology as well as the initial methodological approach decided upon.
Ritchie K, Carriere I, Ritchie CW, et al., 2010, Designing prevention programmes to reduce incidence of dementia: prospective cohort study of modifiable risk factors, BRITISH MEDICAL JOURNAL, Vol: 341, ISSN: 0959-535X
Objective To estimate the percentage reduction in incidence of dementia that would be obtained if specific risk factors were eliminated.Design Prospective seven year cohort study.Setting General population, Montpellier, France.Participants 1433 people aged over 65 with a mean baseline age of 72.5 (SD 5.1) years.Main outcome measures Diagnosis of mild cognitive impairment or dementia established by a standardised neurological examination.Results Cox models were constructed to derive hazard ratios and determine confounding and interaction effects for potentially modifiable risk factors for dementia. Mean percentage population attributable fractions were calculated with 95% confidence intervals derived from bootstrapping for seven year incidence of mild cognitive impairment or dementia. The final model retained crystallised intelligence (population attributable fraction 18.11%, 95% confidence interval 10.91% to 25.42%), depression (10.31%, 3.66% to 17.17%), fruit and vegetable consumption (6.46%, 0.15% to 13.06%), diabetes (4.88%, 1.87% to 7.98%), and apolipoprotein E epsilon 4 allele (7.11%, 2.44% to 11.98%).Conclusions Increasing crystallised intelligence and fruit and vegetable consumption and eliminating depression and diabetes are likely to have the biggest impact on reducing the incidence of dementia, outweighing even the effect of removing the principal known genetic risk factor. Although causal relations cannot be concluded with certainty, the study suggests priorities that may inform public health programmes.
Ritchie K, Ancelin M-L, Beaino E, et al., 2010, Retrospective Identification and Characterization of Mild Cognitive Impairment From a Prospective Population Cohort, AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, Vol: 18, Pages: 692-700, ISSN: 1064-7481
- Author Web Link
- Cite
- Citations: 20
Cerga-Pashoja A, Lowery D, Bhattacharya R, et al., 2010, Evaluation of exercise on individuals with dementia and their carers: a randomised controlled trial, TRIALS, Vol: 11
- Author Web Link
- Cite
- Citations: 25
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.